Absci (ABSI) Interest Expenses (2020 - 2026)
Absci (ABSI) posted Interest Expenses of $8.9 million for Q1 2026, up 30758.62% sequentially from $29000.0 in Q4 2025, and up 54.29% YoY from $5.8 million in Q1 2025.
Analysis
Absci (ABSI) Interest Expenses (2020 - 2026) Analysis & Trends
Absci has reported Interest Expenses for 7 years, with the latest figure at $8.9 million in Q1 2026.
- Quarterly Interest Expenses rose 54.29% year-over-year to $8.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.9 million (up 54.29% YoY) and the FY2025 annual result came in at $106.2 million, up 36.16% from the prior year.
- Interest Expenses improved to $8.9 million in Q1 2026 per ABSI's latest filing, from $29000.0 in the prior quarter.
- Over five years, Interest Expenses peaked at $55.4 million in Q1 2024 and troughed at $29000.0 in Q4 2025.
- A 5-year average of $11.0 million and a median of $5.8 million in 2025 frame the typical range for Interest Expenses.
- The sharpest annual moves came in 2022 and 2023: Interest Expenses soared 9239.78% in 2022, then plunged 93.25% in 2023.
- Over 5 years, Interest Expenses stood at $582000.0 in 2022, then sank by 71.82% to $164000.0 in 2023, then slumped by 33.54% to $109000.0 in 2024, then tumbled by 73.39% to $29000.0 in 2025, then jumped by 30758.62% to $8.9 million in 2026.
- According to Business Quant data, Interest Expenses over the past three periods registered $8.9 million, $29000.0, and $9.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.22 Bn | 132.37 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 86.04 Bn | 78.05 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 63.70 Bn | 58.52 Bn | 1.37 Bn | -1.00 Mn |
| 4 | Moderna | 57.56 Bn | 52.42 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | 23.78 Mn |
| 6 | BeOne Medicines | 40.16 Bn | 35.06 Bn | 1.53 Bn | 39.74 Mn |
| 7 | Alnylam Pharmaceuticals | 35.63 Bn | 32.32 Bn | 992.69 Mn | 82.05 Mn |
| 8 | Royalty Pharma | 28.63 Bn | 27.79 Bn | - | 93.62 Mn |
| 9 | Insmed | 27.73 Bn | 26.57 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Absci | 1.41 Bn | 1.21 Bn | - | 2,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 2,000.00 |
| Mar 31, 2026 | 18,000.00 |
| Dec 31, 2025 | 29,000.00 |
| Sep 30, 2025 | 45,000.00 |
| Jun 30, 2025 | 56,000.00 |
| Mar 31, 2025 | 79,000.00 |
| Dec 31, 2024 | 109,000.00 |
| Sep 30, 2024 | 130,000.00 |
| Jun 30, 2024 | 150,000.00 |
| Mar 31, 2024 | 176,000.00 |
| Dec 31, 2023 | 204,000.00 |
| Sep 30, 2023 | 229,000.00 |
| Jun 30, 2023 | 256,000.00 |
| Mar 31, 2023 | 321,000.00 |
| Dec 31, 2022 | 287,000.00 |
| Sep 30, 2022 | 279,000.00 |
| Jun 30, 2022 | 211,000.00 |
| Mar 31, 2022 | 195,000.00 |
| Dec 31, 2021 | 200,000.00 |
| Sep 30, 2021 | 768,000.00 |